The landscape of metastatic breast cancer (MBC) is one defined by a paradoxical race against time. For patients living with Stage IV disease, every advancement in genomic sequencing and every new clinical trial represents a fragile lifeline. This reality is perhaps most poignantly articulated by Dr. Kelly Shanahan, a physician-turned-advocate who serves as the President of METAvivor. In her most recent address to the MBC community, Shanahan detailed a summer of personal medical setbacks and organizational triumphs, highlighting a pivotal moment in breast cancer advocacy where the lines between patient, doctor, and researcher have become increasingly blurred.
As METAvivor prepares for its high-profile autumn initiatives—including the Stage IV Stampede and the "Light Up MBC" campaign—Shanahan’s personal journey serves as a microcosm of the broader challenges facing the 168,000 Americans currently living with metastatic disease. Her report underscores a critical shift in oncology: the move toward highly personalized, biomarker-driven treatment and the necessity of patient-led legislative advocacy.
Main Facts: A Dual Perspective on Disease Progression
At the core of Dr. Shanahan’s update is a sobering reminder that even for those with the highest levels of medical literacy, MBC remains an unpredictable and relentless adversary. Shanahan, who has lived with MBC for several years, reported that a clinical trial drug that initially showed promise has ultimately failed to control her disease. This failure was not a total systemic collapse but rather a "mixed response"—a common yet frustrating phenomenon in advanced oncology where some tumors shrink while others grow or new ones appear.
The progression of Shanahan’s cancer involved a significant biological shift. Her disease, originally classified as highly ER/PR positive (estrogen receptor/progesterone receptor), mutated into a "low ER/PR" and "HER2 low" status, with new metastases appearing in the liver. This evolution necessitated a radical shift in her treatment protocol, moving her toward a combination of immunotherapy and oral chemotherapy (capecitabine).
Beyond the personal, the "Letter from the President" outlines several major institutional milestones for METAvivor:
- The Launch of a Biomarker Education Program: A new initiative designed to help patients understand the genomic "signatures" of their cancer.
- Legislative Advocacy: The upcoming Stage IV Stampede and Hill Day in Washington, D.C., scheduled for early October.
- Strategic Partnerships: A new collaboration with the "Live from Stage 4" podcast to disseminate research breakthroughs.
- Community Fundraising: The annual "Light Up MBC" event on October 13, which remains the organization’s primary driver for research funding.
Chronology: A Summer of Mutation and Adaptation
The timeline of Shanahan’s recent experience reflects the rapid pace at which MBC can change, requiring constant vigilance and diagnostic agility.
Early Summer: The Clinical Trial Phase
Shanahan began the summer on a clinical trial. In the early stages, the data was encouraging; several metastatic sites showed a positive response to the experimental agent. However, the nature of MBC is characterized by "clonal evolution," where certain cancer cells survive treatment and mutate to bypass the drug’s mechanism of action.
Mid-Summer: The Discovery of Progression
As the summer progressed, physical symptoms emerged—specifically, numbness in a new area of the body—indicating that the cancer had spread. Diagnostic imaging and liquid biopsies confirmed that while some "old" spots remained stable, the cancer had successfully migrated to the liver and changed its molecular profile.
Late Summer: The Pivot to New Modalities
In response to the "high tumor mutational burden" (TMB) identified via liquid biopsy, Shanahan’s "village of oncologists" pivoted. She began a regimen of immunotherapy, which leverages the body’s immune system to recognize and attack mutated cells, alongside capecitabine (Xeloda). As of late August, Shanahan reported a resolution of the numbness, suggesting a positive early response, with formal scans scheduled for the end of the month to confirm the treatment’s efficacy.
Autumn Outlook: Advocacy and Awareness
The chronology moves from the personal to the political as October approaches. This month, traditionally known as Breast Cancer Awareness Month, is often criticized by the Stage IV community for "pink-washing." METAvivor’s timeline focuses instead on "METS Awareness Day" (October 13) and the legislative "Hill Day" (October 6), where patients will lobby for increased federal research funding.
Supporting Data: The Science of Biomarkers and Liquid Biopsies
Shanahan’s experience highlights the critical role of biomarkers in modern oncology. To understand why her treatment changed, one must look at the data provided by advanced diagnostics.
The Shift to "HER2 Low"
Historically, breast cancer was categorized as either HER2-positive or HER2-negative. However, recent clinical data, such as the DESTINY-Breast04 trial, has revolutionized the "HER2 low" classification. Patients who were previously considered HER2-negative but have some HER2 expression (IHC 1+ or IHC 2+/ISH-) now have access to targeted therapies like antibody-drug conjugates (ADCs). Shanahan’s shift to HER2 low status, while a sign of progression, paradoxically opens new doors for targeted treatment.
The Rise of Liquid Biopsies
A cornerstone of Shanahan’s medical advice to the community is the use of liquid biopsies. Unlike traditional tissue biopsies, which require invasive procedures to sample a specific tumor, liquid biopsies (such as Guardant360 or Signatera) analyze circulating tumor DNA (ctDNA) in the blood.
- Sensitivity: Liquid biopsies can detect mutations that tissue biopsies might miss due to "inter-tumor heterogeneity"—the fact that a tumor in the liver may have different mutations than a tumor in the lung.
- Tumor Mutational Burden (TMB): Shanahan’s high TMB was a key data point. High TMB often correlates with a better response to immunotherapy, as the high number of mutations makes the cancer more "visible" to the immune system.
Research Funding Gap
The data surrounding MBC research funding remains a primary motivator for METAvivor. While billions are raised for breast cancer annually, it is estimated that only 7% to 10% of those funds are directed toward metastatic research—the only form of breast cancer that kills. METAvivor remains unique in the non-profit space for its "100% pledge," ensuring that every dollar donated by the public goes directly into research grants.
Official Responses: METAvivor’s Strategic Initiatives
In response to the evolving needs of the MBC community, METAvivor has formalized several programs aimed at education and empowerment.
The Biomarker Education Program
"It is so important when we have a mixed response to treatment that we get biopsies of the new spots," Shanahan emphasized. The new education program is designed to bridge the gap between complex genomic data and patient understanding. By the fall, the organization will host a panel at the Stage IV Stampede and a dedicated webinar focused on "multiple biomarkers"—a scenario where a patient’s cancer expresses several different targets simultaneously, complicating treatment choices.
The R.I.S.E. Initiative
Standing for Reach, Inform, Support, and Empower, the R.I.S.E. initiative represents METAvivor’s commitment to holistic patient care. This program focuses on peer-to-peer support, ensuring that patients newly diagnosed with Stage IV disease do not have to navigate the complex medical and emotional landscape alone.
The Grant Review Process
One of the most distinctive aspects of METAvivor’s operations is the inclusion of patients in the scientific process. Shanahan announced that "patient advocate reviewers" are currently receiving grant applications for the upcoming cycle. These advocates work alongside researchers to ensure that the studies being funded have the highest potential for clinical impact on patient longevity and quality of life.
Implications: The Shift from Awareness to Action
The implications of Dr. Shanahan’s update extend far beyond her personal health. They signal a broader shift in how the metastatic community views its role in the healthcare ecosystem.
From "Pink Ribbon" to "Stage IV Advocacy"
For decades, breast cancer awareness focused on early detection and "survivorship." However, for the metastatic community, there is no "after" cancer. The implication of METAvivor’s fall schedule—specifically the Stage IV Stampede—is that the community is no longer content with "awareness." They are demanding policy changes, such as the Metastatic Breast Cancer Access to Care Act, which seeks to waive the waiting periods for Social Security Disability Insurance (SSDI) and Medicare for those with Stage IV disease.
The Medicalization of the Patient Advocate
Shanahan’s role as a physician-patient highlights the increasing "medicalization" of the advocate. Patients are now expected to understand TMB, ctDNA, and ADC mechanisms. The partnership with the "Live from Stage 4" podcast reflects a need for high-level, sophisticated medical discourse that treats patients as partners in research rather than just subjects of it.
The Future of MBC Funding
As the "Light Up MBC" campaign approaches on October 13, the stakes for fundraising have never been higher. With the emergence of "HER2 low" treatments and new immunotherapies, the "bottleneck" is no longer a lack of biological targets, but a lack of funding to move these targets through the clinical trial pipeline.
In her closing remarks, Shanahan reminded the community that "METAvivor exists for and because of you." It is a sentiment that encapsulates the current state of MBC: a disease that is being fought not just in the lab, but in the halls of Congress and in the personal, often grueling daily lives of patients who refuse to be defined by their diagnosis. As Shanahan waits for her August scans, her story remains a testament to the resilience of a community that is turning its own mortality into a catalyst for scientific and social change.
About the Author
